Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

The Winner Is...

See our winning t-shirt design, created by Mabel, age 7 and order yours in time for April!

Learn More

Patient Engagement

PDF is committed to making patient engagement a reality. Are we there yet?

Learn More

PDF Research

We are funding $5.1 million in research to solve, treat and end Parkinson's.

Learn More

Nurse Training

The Edmond J. Safra Visiting Nurse Faculty Program at PDF announces seven new trainings.

Learn More

The Effects of Exercise on PD

Kristen Pickett, Ph.D., PDF-funded researcher from the University of Wisconsin, Madison reports on her study of exercise and the PD brain.

Learn More 
Your Donations Make a Difference

Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.

Watch Our Video & Learn More

Celebrate Spring New York

Wednesday, April 1 (New York, NY)

Say farewell to winter and Celebrate Spring with us at TAO Downtown. All proceeds benefit the Parkinson’s Disease Foundation. This event is led by PDF and the Young New Yorkers for the Fight Against Parkinson’s committee, including Co-Chairs G. Pennington Egbert III, Gregory and Barbara Romero, Jonathan Romero, Missy Egbert Sheehan and William B. Sheehan and Vice-Chairs W. Alexander Budney, Andrew S. Gustin, George and Peggy Hebard, Josh and Melissa Raskin, Adam and Kim Wolfberg, Darren and Michele Wolfberg.

Learn More

Community Events

View All Upcoming Events = PDF Sponsored Events

VIDEO: FDA Approves DUOPATM for Treatment of Motor Fluctuations in Advanced Parkinson’s Disease

January 12, 2015

PDF alerts the community that DUOPA™, a gel formulation of the drug carbidopa/levodopa that is delivered directly to the small intestine through a surgically-placed tube, has been approved by the US Food and Drug Administration (FDA) for the treatment of motor fluctuations in advanced Parkinson's disease.  The drug’s manufacturer, AbbVie, Inc., announced the approval today. 

See Statement

View All News